Advanced Search
DSpace@MIT

Value creation through modernizing Chinese medicine

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Frank L. Douglas and Anthony J. Sinskey. en_US
dc.contributor.author Sun, Lizhe en_US
dc.contributor.other Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.date.accessioned 2008-09-03T14:55:14Z
dc.date.available 2008-09-03T14:55:14Z
dc.date.copyright 2007 en_US
dc.date.issued 2007 en_US
dc.identifier.uri http://hdl.handle.net/1721.1/42217
dc.description Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2007. en_US
dc.description Includes bibliographical references (leaves 110-114). en_US
dc.description.abstract My first hypothesis in this thesis is that there is significant value vested in traditional Chinese medicine that can be captured by converting them into ethical drugs through scientific analysis, screening and validation. Further, holistic treatment is a key difference between traditional Chinese medicine and western-type chemical drugs, which makes Chinese medicine a very valuable category of knowledge. Using mixed formula is a primary method of treatment in Chinese medicine. It is the application of distinctive medical philosophies of Chinese herbal medicines in practices, reflecting the uniqueness and advantages of Chinese medicine. For example, there are 96,592 mixed formula recorded by "Dictionary of Chinese Medicine Mixed Formula" published in 1997. My second hypothesis in this thesis is that value can be created and captured, under the globalization context, from mixed herbal formulas for the mainstream world market with the aid of fingerprint technologies. To enter western markets as officially approved drugs through critical pathways, both scientific and regulatory, Chinese herb drugs must demonstrate sound evidence for safety and efficacy. I address in this thesis one of the central concerns of the pharmaceutical companies and FDA, that is, how quality control and material consistency is assured and how toxicity and drug kinetics of Chinese herbal medicines, either in its raw form, its purified form, its composite extract form or its mixed formula form, may be measured with reasonable scientific certainty and what would be the likely trajectory of further research. en_US
dc.description.abstract (cont.) My thesis research involves the following aspects: firstly, I characterize, by and through historical review and analysis, the formation of unique Chinese holistic medical philosophy to apply herbal medicines, particularly mixed herbal formulas, to systematically modulate the human body to prevent illnesses, to combat health problems and to restore balanced health; secondly, I performed a comparative study on the regulatory systems between Chinese SFDA and US FDA to provide insights on the trend of harmonic convergence of laws and regulations and challenges going forward, including collection and extrapolation of relevant statistical data; thirdly, I researched emerging fingerprint technologies to address the central issues of standardization, quality control, material consistency, safety and efficacy measurements of Chinese herbal medicines; fourthly, I performed data collection on major Chinese sources of published literatures and patent applications/grants for public and private medicinal knowledge formation, which may be viewed as a surrogate indicator for embedded economic value in the system, to compare trend and gaps between China and developed countries; and lastly, I presented three case studies of development of an-diabetic drugs from herbal sources, to illustrate how value may be created and captured through using modern technologies to tap into the accumulative knowledge base in herbal medicine. The thesis concludes that there are significant values to be captured, by and through cross-border collaborations under the globalization context, from Chinese herbal medicine. Both ethical single molecular entity (singleton) herb-derived drugs and mixed formula herb-derived drugs may be created going forward. en_US
dc.description.statementofresponsibility by Lizhe Sun. en_US
dc.format.extent 118 leaves en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri http://dspace.mit.edu/handle/1721.1/7582 en_US
dc.subject Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.title Value creation through modernizing Chinese medicine en_US
dc.type Thesis en_US
dc.description.degree S.M. en_US
dc.contributor.department Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.identifier.oclc 230935460 en_US


Files in this item

Name Size Format Description
230935460.pdf 9.137Mb PDF Preview, non-printable (open to all)
230935460-MIT.pdf 9.137Mb PDF Full printable version (MIT only)

This item appears in the following Collection(s)

Show simple item record

MIT-Mirage